Comment je traite... certaines pathologies cutanées par le biais de l'immunité innée.

[fr] L’immunité innée repose sur une organisation biologique complexe qui a des implications certaines dans diverses pathologies, en particulier au niveau de la peau. Son fonctionnement dépend de deux piliers principaux qui sont les récepteurs PRR (protein recognition receptor) et des peptides antimicrobiens. Chez l’homme, les principaux PRRs sont les Toll-like récepteurs (TLRs) et les peptides antimicrobiens majeurs comprennant les α- et β-défensines, et la cathélicidines. L’expression de ces composants de l’immunité innée est modulée par certains médicaments, ce qui représente un mode d’action qui était resté ignoré par le passé.

Disciplines :

Dermatology

Author, co-author :

Pierard-Franchimont, Claudine ; centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

English

Title :

Comment je traite... certaines pathologies cutanées par le biais de l'immunité innée.

Publication date :

2008

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Pages :

699-701

Peer reviewed :

Peer reviewed

Available on ORBi :

since 06 February 2009

Statistics

Number of views

95 (3 by ULiège)

Number of downloads

136 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Flagothier C, Uhoda E, Goffin V, et al. - Biocénose cutanée, peptides antimicrobiens cutanés et antiseptiques. Dermatol Actual, 2004, 86, 22-24.
Braff MH, Bardan A, Nizet V, Gallo RL. - Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol, 2005, 125, 9-13.
Izadpanah A, Gallo RL. - Antimicrobial peptides. J Am Acad Dermatol, 2005, 52, 381-390.
Bowdish DM, Davidson DJ, Hancock RE. - Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbiol Immunol, 2006, 306, 27-66.
Zheng Y, Niyonsaba F, Ushio H, et al. - Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human α-defensins from neutrophils. Br J Dermatol, 2007, 157, 1124-1131.
Yamasaki K, Gallo RL. - Antimicrobial peptides in human skin disease. Eur J Dermatol, 2008, 18, 11-21.
Beg AA. - Endogenous ligands of Toll-like receptors : implications for regulating inflammatory and immune responses. Trends Immunol, 2002, 23, 509-512.
Metz M, Siebenhaar F, Maurer M. - Mast cell functions in the innate skin immune system. Immunobiology, 2008, 213, 251-260.
Pernet I, Reymermier C, Guezennec A, et al. - An optimized method for intensive screening of molecules that stimulate β-defensins 2 or 3 (hBD2 or hBD3) expression in cultured normal human keratinocytes. Int J Cosmet Sci, 2005, 27, 161-170.
Koreck A, Pivarcsi A, Dobozy A, Kemény L. - The role of innate immunity in the pathogenesis of acne. Dermatology, 2003, 206, 96-105.
Donnarumma G, Paoletti I, Buommino E, et al.- Malassezia furfur induces the expression of β-defensin-2 in human keratinocytes in a protein kinase C-dependent manner. Arch Dermatol Res, 2004, 295, 474-481.
Roeder A, Kirschning CJ, Rupec RA, et al. - Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol, 2004, 42, 485-498.
Baroni A, Orlando M, Donnarumma G, et al. - Toll-like receptor 2 (TLR2) mediates intracellular signalling in human keratinocytes in response to Malassezia furfur. Arch Dermatol Res, 2006, 297, 280-288.
Kawai M, Yamazaki M, Tsuboi R, et al. - Human beta-defensin 2, an antimicrobial peptide is elevated in scales collected from tinea pedis patients. Int J Dermatol, 2006, 45, 1389-1390.
Jensen JM, Pfeiffer S, Akaki T, et al. - Barrier function, epidermal differentiation, and human beta-defensin 2 expression in tinea corporis. J Invest Dermatol, 2007, 127, 1720-1727.
Speth C, Rambach G, Würzner R, Lass-Flörl C. - Complement and fungal pathogens : an update. Mycoses Epub, 2008, Aug. 13.
Howell MD. - The role of human beta defensins and cathelicidins in atopic dermatitis. Curr Opin Allergy Clin Immunol, 2007, 7, 413-417.
Marshak-Rothstein A, Rifkin IR. - Immunologically active autoantigens : the role of Toll-like receptors in the development of chronic inflammatoyr disease. Annu Rev Immunol, 2007, 25, 419-441.
Yamasaki K, Di Nardo A, Bardan A, et al. - Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Med, 2007, 13, 975-980.
Gambichler T, Skrygan M, Appelhans C, et al. - Expression of human beta-defensins in patients with mycosis fongoides. Arch Dermatol Res, 2007, 299, 22.
Schön MP, Schön M.- Imiquimod : mode of action. Br J Dermatol, 2007, 157, S8-S13.
Quatresooz P, Piérard GE. - Imiquimod-responsive basal cell carcinomas and Factor XIIIa-enriched dendrocytes. Clin Exp Dermatol, 2003, 28, S27-S29.
Piérard-Franchimont C, Nikkels AF, Paquet P, et al. - Comment je traite... un carcinome basocellulaire par l'imiquimod topique (Aldara®). Rev Med Liège, 2005, 60, 207-209.
Quatresooz P, Piérard-Franchimont C, Paquet P, et al. - Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol, 2008, 18, 6-10.
Hermanns-Lê T, Paquet P, Nikkels AF, et al. - Prolonged imiquimod treatment and graft-versus-host reaciton : histological mimicry in the pattern of monocyte-macropahge-dendrocyte lineage skin infiltration. Dermatology, 2003, 206, 361-365.
Uhoda I, Quatresooz P, Piérard-Franchimont C, Piérard GE. - Nudging epidermal field cancerogenesis by imiquimod. Dermatology, 2003, 206, 357-360.
Piérard-Franchimont C, Nikkels AF, Henry F, et al. - L'imiquimod : sus aux kératoses actiniques et à la cancérogenèse en champ. Dermatol Actual, 2007, 102, 8-10.
Piérard GE, Piérard-Franchimont C, Paquet P, Quatresooz P. - Emerging therapies for ionizing radiation-associated skin field carcinogenesis. Expert Opin Pharmacother, sous presse.
Bourguignon R, Paquet P, Quatresooz P, Piérard GE. - Comment je traite... un lentigo malin apr l'imiquimod topique (Aldara®). Rev Med Liège, 2005, 60, 691-694.
Arrese JE, Paquet P, Claessens N, et al. - Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol, 2001, 28, 131-134.
Kanzler H, Barrat FJ, Hessel EM, Coffman RL. - Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med, 2007, 13, 552-559.
Harder J, Meyer-Hoffert U, Wehkamp K, et al.- Differential gene induction of human β-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol, 2004, 123, 522-529.
Pournaras CC, Lubbe J, Saurat H. - Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J Invest Dermatol, 2001, 116, 480-481.
Xhauflaire-Uhoda E, Piérard-Franchimont C, Nikkels AF, Piérard GE. - Comment je préviens... une exacerbation de dermatite atopique. Rev Med Liège, 2006, 61, 600-603.